← Leaderboards
Alice Marcy
Dynamis Therapeutics, Inc.
$128,790
Attributed
$257,579
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding mix
By agency
NIH$257,579 · 1
By mechanism
R43$257,579 · 1
Top collaborators
- Melvin Reichman1 shared
Most similar at Dynamis Therapeutics, Inc.
Same institution · by research overlap
- Michael L Schwartz$2,635,603
- William C Randall$100,000
Others in their field
Top investigators on “Advanced Glycosylation End Products”
- Ann Marie Schmidt · Beckman Research Institute/City Of Hope$16,947,325
- Jose A Luchsinger · Columbia University Health Sciences$11,327,382
- Gary E Gibson · Winifred Masterson Burke Med Res Inst$10,842,701
- Howard Feldman · University Of California, San Diego$10,098,461
- Ram H Nagaraj · Case Western Reserve University$9,627,678
- Michal Schnaider Beeri · Icahn School Of Medicine At Mount Sinai$7,313,968
Research focus
Advanced Glycosylation End ProductsAnimal ModelBiochemicalCellsCollectionComplications Of Diabetes MellitusCounterscreenCytotoxicDiabetes MellitusDiabeticDrug CandidateDrug KineticsEnzymesFollow-UpFructosamine-3-KinaseGlucoseHexosesHigh Throughput ScreeningImmunoassayInhibitor/AntagonistInhibitory Concentration 50Kidney DiseasesKinase Inhibitor3-Deoxyglucosone